Global Pegfilgrastim Biosimilars Market

Biosimilar monoclonal antibodies refer to a member of the family of biosimilars. Large, intricate proteins are typically given as part of the treatment for conditions like cancer or rheumatoid arthritis. They are employed by the immune system to recognise and destroy foreign substances, including bacteria, viruses, and others. The main types of biosimilar monoclonal antibodies are synthetic chemicals, biopharmaceuticals, and others. Any pharmaceutical drug product made from, derived from, or semi-synthesized from biological sources is known as a "biopharmaceutical," sometimes known as a "biologic medical product," or "biologic. The different compounds include infliximab, rituximab, abciximab, trastuzumab, adalimumab, and bevacizumab and are used in various applications such as chronic and autoimmune diseases, oncology, and others. The biosimilar monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides biosimilar monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a biosimilar monoclonal antibodies market share, detailed biosimilar monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar monoclonal antibodies industry. This biosimilar monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar monoclonal antibodies market grew from $5.47 billion in 2022 to $6.63 billion in 2023 at a compound annual growth rate (CAGR) of 21.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar monoclonal antibodies market is expected to grow from $11.29 billion in 2027 at a CAGR of 14.3%. The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American Cancer Society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases, including cancer, is expected to drive the biosimilar monoclonal antibodies market. Stringent regulations imposed on approvals of biosimilars are anticipated to hinder the growth of the biosimilar monoclonal antibody market. The governments of different regions impose different rules regarding the production and use of biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercialising the government-approved biosimilars. The US Food and Drug Administration requires double regulatory approval for biosimilars, restricting the use of biosimilars as interchangeable drugs for biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars, only 7 biosimilars, including 4 originating biologics, could enter the US commercial market. The strict government policies for approval of these drugs negatively impact manufacturers in the biosimilar monoclonal antibody market. The focus areas for many companies in the biosimilar monoclonal antibody market have shifted to mergers and acquisitions to acquire more production capabilities. Large prime manufacturers are forming joint ventures or buying small or midsized companies to acquire new capabilities, or to gain access to new markets. For instance, Aurobindo Pharma Limited acquired four cell culture-derived biosimilar products from TL Biopharmaceutical AG of Switzerland. As part of the agreement, TL will supply all the developmental data for four molecules, and Aurobindo and/or its affiliates will develop, commercialize, and market these products globally. Out of the four biosimilars acquired, three of them are monoclonal antibodies in oncology. In another case, in May 2020, AbbVie, a biopharmaceutical company based in the United States, announced its intention to acquire Allergan for $63 million.This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership position in biosimilar monoclonal antibodies. In May 2020, AbbVie, a US-based biopharmaceutical company, acquired Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports maintaining its leadership position in biosimilar monoclonal antibodies. Allergan is an Ireland-based pharmaceutical company that manufactures, develops, and markets drugs, biosimilars, medical devices, eye care, and others. Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited. North America was the largest region in the biosimilar monoclonal antibodies market in 2022. The regions covered in the global biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar monoclonal antibodies market consists of sales of Blitzima, Ritemvia, Rituzena, and Truxima. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar monoclonal antibodies market is segmented - 1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types 2) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications 3) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

Biosimilar therapeutic peptides refer to a peptide drug that is used in place of or in addition to peptide hormones when endogenous levels tend to decline. Therapeutic peptides that are biosimilar have applications in the treatment of cancer, metabolic, pulmonary, cardiovascular, and other illnesses. The two main types of biosimilar therapeutic peptides are innovative and generic. Biosimilar medications are frequently mistaken for generic drugs. Both are marketed as low-cost knockoffs of high-priced name-brand medications. The main distinction is that generics are duplicates of synthetic pharmaceuticals, whereas biosimilars are based on drugs that contain biological organisms as active components. The different routes of administration include the parenteral route, the transdermal route, and others and are used in cancer, cardiovascular disorders, central nervous system, metabolic disorders, infections, haematological disorders, gastrointestinal disorders, dermatology, and respiratory disorders. The biosimilar therapeutic peptides market research report is one of a series of new reports from The Business Research Company that provides biosimilar therapeutic peptides market statistics, including global market size, regional shares, competitors with a biosimilar therapeutic peptides market share, detailed biosimilar therapeutic peptides market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilar therapeutic peptides industry. This biosimilar therapeutic peptide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar therapeutic peptides market grew from $1.21 billion in 2022 to $1.58 billion in 2023 at a compound annual growth rate (CAGR) of 30.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar therapeutic peptides market is expected to grow from $3.9 billion in 2027 at a CAGR of 25.3%. The increasing ageing population is projected to surge the number of patients with chronic diseases, contributing to the biosimilar therapeutic peptides’ market's growth. Elderly people are more prone to various chronic diseases, which are surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the number of people aged 80 and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancers. The expected increase in the ageing population suffering from various chronic conditions will drive the biosimilar market. The long and costly drug approval process is expected to limit the growth of the biosimilar therapeutic peptide market over the upcoming years. The development, approval, and launch of new drugs is an expensive and prolonged procedure that includes expensive research stages. A new drug has to go through four phases of clinical trials and screening by the regulatory body, including the Food and Drug Administration (FDA) (USA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), and the Medicines and Healthcare Products Regulatory Agency (MHRA) (India). For instance, in September 2020, according to an article shared by Proclinical, a UK-based recruitment agency in the life sciences sector, the average cost to create a new drug is close to $4 billion, however, this cost might occasionally reach $10 billion. No other sector invests more in R&D than the semiconductor industry. According to a recent research, R&D costs are predicted to climb by 3% annually and surpass $203 billion by 2024, therefore, this trend is only projected to continue. Therefore, a long and costly drug approval process is anticipated to hinder the growth of the biosimilar therapeutic peptide market. During the forecast period, the biosimilar therapeutic peptides market is expected to witness growth in research collaborations as well as research funding approvals. Collaborations with other companies and organisations are being prioritised by key companies in order to improve research and development, expand product portfolios, and expand geographical reach.For instance, in January 2020, a UK-based biotechnology company focusing on developing a class of therapeutics based on its proprietary bicyclic peptide technology announced a collaboration with Cancer Research UK to develop BT7401, a new bicyclic immuno-oncology candidate. Cancer Research UK will fund and sponsor the development of a new candidate. In addition to this, Sapience Therapeutics, Inc., a US-based biotechnology company focused on the research & development of peptide therapeutics, announced a research collaboration with the University of Bath (UK) to develop and discover new therapeutic agents for oncology applications. Hence, research collaborations to develop new therapeutic peptides are a major trend in the market. In September 2020, Ligand Pharmaceuticals Incorporated, a US-based biopharmaceutical company, acquired Pfenex Inc. for an undisclosed amount. The acquisition would provide Ligand access to its proprietary protein expression technology. The transaction has the potential to have a materially beneficial scientific and financial impact on our business in the immediate and long terms. Pfenex would provide Ligand with a well-established, tested protein expression platform that would provide a great complement to our vital, exclusive drug discovery and formulation technologies. Pfenex Inc. is a US-based manufacturer of biosimilars, including teriparatide, ranibizumab, and pegfilgrastim. Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC., GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. North America was the largest region in the biosimilar therapeutics market in 2022. The Middle East is expected to be the fastest growing region in the global biosimilar therapeutic peptides market during the forecast period. The regions covered in the global biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar therapeutic peptides market consists of sales of pegfilgrastim, bevacizumab, and adalimumab. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar therapeutic peptides market is segmented - 1) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations 2) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders 3) By Type: Innovative, Generic

Rituximab biosimilar refers to a chimeric monoclonal antibody that is directed against the immune system's B cell-specific protein CD20. Rituximab kills B cells, making it useful for treating conditions where there are too many, too active, or otherwise abnormal B cells. The main routes of administration for rituximab biosimilars are subcutaneous, intravenous, and molecular. Intravenous therapy is a medical procedure in which fluids, drugs, and nutrients are delivered straight into a patient's vein. The different applications include non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others, and are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, and other direct distribution channels. The rituximab biosimilars market research report is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market statistics, including rituximab biosimilars industry global market sizes, regional shares, competitors with a rituximab biosimilars market share, detailed rituximab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the rituximab biosimilars industry. This rituximab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global rituximab biosimilars market grew from $2.05 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 14.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The rituximab biosimilars market is expected to grow from $3.84 billion in 2027 at a CAGR of 13.1%. The rising prevalence of non-Hodgkin's lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin's lymphoma, or lymphoma, is cancer that starts in white blood cells, and lymphocytes that are part of the body’s immune system. According to the American Cancer Society, NHL is the most common cancer in the USA, accounting for about 4% of all cancers. In the United States, approximately 81,560 people (45,630 men and 35,930 women) will be diagnosed with NHL in 2021.Thus, growing cases of non-Hodgkin's lymphoma are predicted to generate high demand for rituximab biosimilars over the forecast period. The high cost associated with rituximab biosimilars acts as a major restraint for the growth of rituximab’s market over the upcoming years. The cost of the subcutaneous option was costlier than IV biosimilar rituximab. Subcutaneous formulation costs between $3,805 and $8,807 for patients with small bodies, and between $325 and $6109 and $484 and $6267 for patients with medium bodies for two infusion speeds.The high costs of rituximab biosimilars make it unaffordable for the treatment of patients with low income, hindering the growth of the market. The companies operating in the biosimilars industry are continuously focusing on new product development in collaboration with other companies operating in the industry. Innovations through partnerships are shaping the market for rituximab biosimilars. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd. jointly announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche's Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Co. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd. North America was the largest region in the rituximab biosimilars market in 2022. The Middle East is expected to be the fastest-growing region in the global rituximab biosimilars market during the forecast period. The regions covered in the global rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The rituximab biosimilar market consists of sales of mabthera, truxima, ruxience, or rixathon. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global rituximab biosimilars market is segmented - 1) By Application: Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis, Other Applications 2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels 3) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type

Biosimilar hormones refer to the hormones included in the product that are chemically identical to those produced by your body. In fact, it's possible that the hormones in bioidentical drugs are identical to those used in conventional hormone therapy. They are used to treat people whose hormone levels are low or out of whack. The main types of biosimilar hormones are teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars and others. Teriparatide is a parathyroid hormone recombinant (PTH). Teriparatide is similar to a component of human PTH, and when taken regularly, it stimulates osteoblasts more than osteoclasts, increasing bone mass. The different applications include research and biotechnology, diagnostics, biocatalysts, therapeutics, and others and are distributed through various channels such as hospital and retail pharmacies, online pharmacies or e-pharmacy, and specialty clinics. The biosimilar hormones market research report is one of a series of new reports from The Business Research Company that provides biosimilar hormones market statistics, including biosimilar hormones industry global market size, regional shares, competitors with a biosimilar hormones market share, detailed biosimilar hormones market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar hormones industry. This biosimilar hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar hormones market grew from $2.31 billion in 2022 to $3.03 billion in 2023 at a compound annual growth rate (CAGR) of 31.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar hormones market is expected to grow from $7.68 billion in 2027 at a CAGR of 26.2%. The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years, and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market. For instance, in January 2022, according to the British Medical Journal, a UK-based peer-reviewed medical trade journal, the prevalence of GH deficiency (GHD) in children is thought to range from 1 in 3500 to 1 in 10000 across the globe. Also, in June 2022, according to a Medscape report, about 6,000 adults are expected to be diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market. Stringent regulations imposed on the approval of hormone biosimilars limit the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market. Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launches in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products in various locations to boost sales and maximise profits. For instance, in February 2022, Alvotech Holdings S.A., a Luxembourg-based biopharmaceutical company specialising in the development of biosimilar medicines, announced partnerships with Fuji Pharma Co. Ltd., a Japan based pharmaceutical company, to develop biosimilar drug candidates in Japan. Through this partnership, both companies have decided to add new elements to their strategic alliance for the creation and marketing of biosimilar medicines in Japan. Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma. North America was the largest region in the biosimilar hormones market in 2022. The regions covered in the global biosimilar hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The biosimilar hormones market consists of sales of estrace, estradil, and estring. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar hormones market is segmented - 1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types 2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications 3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/e-pharmacy, Specialty Clinics

Immune-regulating lymphocyte modulators that produce biosimilars are referred to as biosimilar lymphocyte modulators.Lymphocyte modulators are intended as an aid in the treatment for cancer and autoimmune diseases, and for regulating carotene intake in humans with a weak immune system. The main types of drugs in biosimilar lymphocyte modulators are Campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar), anti-CD38 daratumumab biosimilar, and anti-CS1 elotuzumab biosimilar. Campath is a prescription medication used to treat the symptoms of CLL. Campath can be taken on its own or in combination with other drugs. The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, and others. By distribution channel, it is segmented into online pharmacies and direct to consumers. The biosimilar lymphocyte modulator market research report is one of a series of new reports from The Business Research Company that provides biosimilar lymphocyte modulator market statistics, including biosimilar lymphocyte modulator industry global market size, regional shares, competitors with a biosimilar lymphocyte modulator market share, detailed biosimilar lymphocyte modulator market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar lymphocyte modulator industry. This biosimilar lymphocyte modulator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar lymphocyte modulator market grew from $1.34 billion in 2022 to $1.52 billion in 2023 at a compound annual growth rate (CAGR) of 13.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar lymphocyte modulator market is expected to grow from $2.32 billion in 2027 at a CAGR of 11.2%. Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market. The combination of immunotherapies or pairing of immunotherapies with other types of cancer treatments, such as chemotherapy or radiation, enhances the benefit associated with lymphocyte modulators. In December 2021, according to a study conducted by the researchers at Washington University School of Medicine in St. Louis, pre-activated natural killer cells will have been shown in a limited clinical trial to be helpful for some adolescents and young adults with recurrent AML who have few other therapeutic choices. Combining the therapies helps determine whether alternative chemotherapy can improve the killing of leukaemia cells, and researchers have combined memory-like natural killer cells to see if this is possible.The combination approach, therefore, saves patients’ lives from a life-threatening reaction of the immune system, thereby driving the growth of the lymphocyte modulator market. The shortage of raw materials for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market. Drug shortages are due to several factors, including challenges in acquiring raw materials, manufacturing problems, regulatory issues, business decisions, and numerous disturbances within the supply chain. They adversely affect patient care by causing the replacement of safe and effective therapies with elective medicines, compromising or delaying medical procedures, or causing medication errors. The American Society of Haematology, an association comprising clinical scientists and physicians that provides care to patients in diverse settings, sent a letter to the US Food and Drug Administration highlighting the issue of the shortage of critical hematologic drugs such as etoposide and methotrexate, which have no alternatives. The chemotherapeutic drug etoposide, in particular, is an important component in treatment regimens designed to be curative for life-threatening conditions such as leukaemia and lymphomas.Due to the shortage, some patients have received less effective treatment. Thus, the raw material shortages cause delayed and compromised medical treatments and also result in limiting the growth of the market. Tumor-Infiltrating Lymphocyte Immunotherapy has been gaining popularity in recent times because of its positive results in anti-cancer treatments. Tumor-infiltrating lymphocytes (TILs) comprise of all lymphocytic cell populaces that have occupied the tumour tissue. TILs have been depicted in various solid tumors, including breast cancer, and are emerging as a significant biomarker in predicting the efficacy and result of treatment. Due to promising results, many companies have started launching TIL technologies. For instance, in January 2020, Lovance Biotherapeutics, a US-based start-up company, licenced TALEN technology from Cellectis to develop gene-editing tumor-infiltrating lymphocytes (TIL) to treat several cancer indications. Other companies investing in TIL technology are Optera Therapeutics Corp and TILT Biotherapeutics. In July 2020, Cytocom, Inc., a US-based immunotherapy generating company, announced the acquisition of ImQuest Life Sciences, Inc. for an undisclosed sum. The deal is expected to support Cytocom’s vision of strategic growth, strengthen internal drug development programmes with new assets, and secure revenue-generating operations, scientific resources, and tools, and capacity. ImQuest Life Sciences is a US-based company with leading drug discovery and development capabilities. The company was founded in 2004. Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis, and Celltrion. North America was the largest region in the biosimilar lymphocyte modulator market in 2022. The Middle East is expected to be the fastest-growing region in the global biosimilar lymphocyte modulator market during the forecast period. The regions covered in the global biosimilar lymphocyte modulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar lymphocyte modulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar lymphocyte modulator market consists of sales of roasted coffee, coffee concentrates, coffee extracts, flavorings, and syrups. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar lymphocyte modulator market is segmented - 1) By Drug: Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar 2) Distribution Channel: Online Pharmacies, Direct-to-Consumer 3) By Disease: Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis, Other Diseases

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs. The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others. The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilars market grew from $19.1 billion in 2022 to $23.28 billion in 2023 at a compound annual growth rate (CAGR) of 21.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilars market is expected to grow from $47.82 billion in 2027 at a CAGR of 19.7%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market. The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of familiarity with biosimilars reduces the likelihood of prescribing the drugs to patients which affects the demand for new biosimilars in the market. For instance, according to the PwC’s Health Research Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the biosimilars market. Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in August 2020, Biocon Biologics India Ltd., an India-based fully integrated global biosimilars organization, in partnership with Mylan, a US-based biosimilar company, has launched Semglee, insulin glargine injection in the U.S. to aid in lowering blood sugar levels in adults with type 2 diabetes and children with type 1 diabetes. Major players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, STADA Arzneimittel, Sandoz International, Samsung Bioepis, Teva Pharmaceuticals, Apotex, AMEGA Biotech S.A., Bioton S.A., Innovent Biologics International, Allergan PLC., BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupin Merck, Novartis, Ratiopharm, Wockhardt, Zydus Cadila, Allergan PLC., Hospira International., Actavis International., Johnson & Johnson and Roche. North America was the largest region in the global biosimilars market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilars market is segmented - 1) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins 2) By Types: Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Other Types 3) By Application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies. The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oncology biosimilars market grew from $4.19 billion in 2022 to $5.38 billion in 2023 at a compound annual growth rate (CAGR) of 28.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology biosimilars market is expected to grow from $12.83 billion in 2027 at a CAGR of 24.3%. The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars. The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market. The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plan to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up an R&D facility to boost biosimilar development. Major players in the oncology biosimilars market are Bitcoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan, and F Hoffmann-La Roche. North America was the largest region in the global oncology biosimilars market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the global oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology biosimilars market is segmented - 1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Filgrastim Biosimilars Market Definition